ABOUT HEMGENIX

Number of eligible patients: CDEC discussed the uncertainty in the number of people with moderately extreme to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some clients that are labeled as obtaining moderate or reasonable condition might have a serious bleeding